Ultrastructural Changes in Rat’s Atrial Cardiomyocytes After Short Term Administration of Amiodarone and Possible Protective Role of Vitamin E by Shatoor, Abdullah S. et al.
Original Article J Clin Med Res  •  2012;4(3):190-196
ress Elmer 
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited
Ultrastructural Changes in Rat’s Atrial Cardiomyocytes 
After Short Term Administration of Amiodarone and 
Possible Protective Role of Vitamin E
Abdullah S. Shatoora, Mohamed Samir Ahmad Zakib, d, 
Refaat A. Eidc, Mohamed A. Sayed-Ahmadb
Abstract
Background: Amiodarone chlorhydrate is a diiodated benzofuran 
derivative used to treat a variety of cardiac rhythm abnormalities. 
The use of amiodarone is associated with ultrastructural changes 
affecting body tissues, but its effect on the ultrastructure of the heart 
has not yet been fully elucidated.
Methods: The aim of this study is to test the adverse effects of 
amiodarone administration on cardiomyocytes and to study the pos-
sible protective role of vitamin E co-administration. A total of 18 
adult male albino rats were used in this study. The rats were divided 
randomly into three groups of 6 rats each as follows: group I was 
considered the control group and was given vegetable oil; group 
II received 54 mg/kg of oral amiodarone; and group III received a 
single dose of combined vitamin E (50 mg/kg) and amiodarone (54 
mg/kg). After 2 weeks, the rats were sacrificed, and the atrial tissues 
were harvested and processed for electron microscopic study.
Results: Administration of amiodarone alone modified the atrial 
architecture, which was demonstrated by the following: mitochon-
drial enlargement and cristae lysis; marked heterogeneity of myo-
fibril patterns with partial necrosis and disintegration of myofila-
ments; and irregularities of the sarcomere and less concentration 
of atrionatriuretic factor (ANF) granules, which localised in closed 
proximity to the nucleus with disrupted chromatin contents. Con-
comitant administration of vitamin E with amiodarone showed a 
considerable preservation of the atrial architecture.
Conclusions: Oral administration of amiodarone in rats resulted in 
ultrastructural changes in atria, which can be attenuated by vitamin 
E co-administration.
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Introduction
It is well established that long-term oral administration of 
amiodarone  is  extremely  effective  in  the  management  of 
most supraventricular and ventricular tachyarrhythmias [1, 
2]. Amiodarone is categorised as a class III antiarrhythmic 
agent, as it prolongs the atrial and ventricular action poten-
tial duration (APD) as well as the refractory period of car-
diac muscle. These effects are potentiated when the drug is 
given for longer durations [3].
Compared to the action of most available antiarrhythmic 
agents, the oral administration of amiodarone has a nega-
tive inotropic effect of lower significance and is less proar-
rhythmic, making it advantageous for use in patients with 
impaired ventricular function [4, 5]. On the contrary, intra-
venous administration of amiodarone in studies conducted 
on dogs resulted in considerable reduction of myocardial 
contractility [6, 7].
In spite of these advantages, adverse effects caused by 
amiodarone are frequent and can be serious and even lethal. 
Such reactions involve the liver [8], lungs [9-11], cornea 
[12], skin [13] and thyroid gland [14]. Evidence from in 
vitro and in vivo studies has attributed the pathogenesis of 
amiodarone toxicity to oxygen free radicals and oxidative 
stress [9, 10]. However, other studies do not support these 
findings. The effects of amiodarone on the mitochondrial 
oxidation of fatty acids in the liver of mice were determined 
[15-18]. Characteristic lamellar lysosomal inclusion bodies 
representing  phospholipidosis  were  found  in  microscopi-
cally studied liver specimens [17].
Vitamin E (α-tocopherol) is thought to protect tissues 
Manuscript accepted for publication April 30, 2012
aInternal Medicine Department, Cardiology Section, Faculty of 
 Medicine, King Khalid University, Saudi Arabia
bAnatomy Department, Faculty of Medicine, King Khalid University, 
 Saudi Arabia  
cPathology Department (Electron Microscopy Unit), Faculty of 
 Medicine, King Khalid University, Saudi Arabia
dCorresponding author: Mohamed Samir Ahmed Zaki, Histology and 
 Cytology (Anatomy) Department, College of Medicine, King Khalid 
 University (KKU), Abha 24121 Saudi Arabia. 
 Email: mszaki1@hotmail.com
doi:10.4021/jocmr909w
190                                                                                                                                                                                                                                                                                                                                                                                                                                             191J Clin Med Res  •  2012;4(3):190-196 Shatoor et al
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
by reducing or preventing oxidative damage. This lipid sol-
uble vitamin prevents lipid peroxidation chain reactions in 
cellular membranes by interfering with the propagation of 
lipid radicals. Recent histological and immunohistochemical 
studies have shown a protective role of vitamin E against 
oxidative stress injury and alteration in the architecture of 
liver and lungs of rats that received amiodarone [19, 20].
Therefore, the aim of the present study is to assess the 
ultrastructural changes of the rat heart after amiodarone ad-




Amiodarone (Chlorhydrate D’) was purchased from Sanofi 
(France), and alpha tocopherol acetate was purchased from 
Sigma-Aldrich (Buchs, Switzerland). Both compounds were 
used without further purification.
Drug preparation
Amiodarone alone or combined with alpha tocopherol ac-
etate were dissolved in 2 mL vegetable oil to their final con-
centration according to the weight of each animal. The doses 
of amiodarone and alpha tocopherol acetate used in this ex-
periment were 54 mg/kg and 50 mg/kg, respectively. The 
dose of amiodarone selected in this study corresponds to the 
maximum human daily therapeutic dose converted into the 
equivalent rat dose according to Paget’s table [21]. The dose 
of alpha tocopherol was chosen as an effective antioxidant 
dose in rats according to Calfee-Mason et al [22].
Experimental animals
The study was carried out in the Department of Anatomy 
at the College of Medicine, King Khalid University (Abha, 
Saudi Arabia) in October, 2011. Eighteen adult male albino 
Wistar rats weighing between 200 - 250 g and aged 6 months 
were used for the experimental procedure. The rats were ob-
tained from the animal house of the College of Medicine, 
King Khalid University, Abha, Saudi Arabia. All rats were 
maintained in similar polypropylene cages of standard di-
mensions at a temperature of 25 ± 1oC and a standard 12 h 
day/night cycle; the rats were housed in groups of 4 rats per 
cage (50 x 26 x 16 cm). The rats were fed rat chow and wa-
ter ad-libitum. All procedures were approved by the Ethical 
Committee at King Khalid University Medical School and 
Figure 1. Electron micrographs from cardiac atria of control rats. A. A semithin section showing clarified intercalated discs (arrows), 
typical cross striations of muscle fibres (star), and many rows of mitochondria (double arrows). (B) blood capillary. B. The striation 
pattern (stars) with its typical alteration and dense mitochondria (M) rich in cristae (Bar = 200 nm). C. The striation pattern (stars) with 
its typical alteration and dense mitochondria (M) rich in cristae, euchromatic nucleus (N) with its nucleolus (n) and closely packed 
atrionatriuretic factor (ANF) granules (An) (Bar =1 µm). D. The striation pattern (stars) with its typical alteration and step-like interca-
lated disc (arrow) with adherent fascia (Bar = 500 nm). (x: 1000).
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were performed in agreement with the Principles of Labo-
ratory Animal Care, advocated by the National Society of 
Medical Research and the Guide for the Care and Use of 
Laboratory Animals and published by the National Research 
Council [23].
Experimental procedure
The rats were divided randomly into 3 groups of 6 rats each. 
All drugs were given in a final volume of 2 mL/day, orally 
using intra-gavage stainless steel needle for 2 weeks. The 
groups  of  rats  were  classified  as  follows:  (a)  the  control 
group received vegetable oil; (b) group 2 received amioda-
rone (54 mg/kg) alone; and (c) group 3 received both amio-
darone (54 mg/kg) and alpha tocopherol acetate (50 mg/kg).
 
Preparation of atrial tissue for electron microscopy
After  the  treatment  period,  small  pieces  of  the  harvested 
atrial cardiac muscle were fixed in 2.5% glutaraldehyde for 
24 hours and washed by phosphate buffer (0.1 M, pH 7.4). 
Post fixation was made in 1% osmium tetroxide buffered to 
pH 7.4 with 0.1 M phosphate buffer at 4 oC for 1 - 2 hours. 
Specimens were washed again in phosphate buffer to remove 
excess fixative and dehydrated through ascending concentra-
tions of ethanol. The specimens were then cleared in pro-
pylene oxide and embedded in araldite. Polymerisation was 
obtained by placing the capsules at 60 oC. Ultra-thin sections 
(100 nm) were prepared using an ultra microtome and were 
placed on uncoated copper grids. Following double staining 
with uranyl acetate and lead citrate, sections were examined 
and photographed using a JEOL transmission electron mi-
croscope [24]. The specimens were prepared and read by a 




Group I (Control group)
 
Electron microscopic examination of the sections from the 
rat atria of the control group showed normal architecture. 
The mitochondria were packed together between myofibrils 
with some beneath the sarcolemma and some around the nu-
cleus with visible intercalated discs (Fig. 1A). The striation 
pattern, with its typical alteration and dense mitochondria 
rich in cristae, was clearly visible in cardiac muscle (Fig. 1B, 
Figure 2. Electron micrographs from cardiac atria of amiodarone-treated rats. A. A semithin section showing abnormal pattern of 
striations (stars), disrupted intercalated discs (arrow) and abnormal mitochondrial arrangements (double arrows). B. Dissociation of 
myofibrils (stars) with irregularities and destruction of myofibrils and intercalated disc (arrow) (Bar = 200 nm). C. Dissociation of myo-
fibrils (stars) with irregularities of the sarcomere and lesser concentration of ANF granules (An) with disrupted nuclear (N) chromatin 
contents (Bar = 1 µm). D. Swollen mitochondria (M) with loss of its cristae in some and loss of its pattern in others. Empty spaces in 
between myofibrils (m) and fibres (F) were noted in the intercellular space (Bar = 1 µm). (x: 1000).
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1C). The euchromatic nucleus with its nucleolus and closely 
packed  large  atrionatriuretic  factor  (ANF)  granules  were 
noted (Fig. 1C). Higher magnification of step-like interca-
lated discs was revealed tight junctions and desmosomes 
(Fig. 1D).
Group II (Amiodarone treated rats)
Sections from atria of rats administered amiodarone alone, 
showed ultrastructural changes. Loss of myocardial organi-
sation, a scattered area of degenerated cardiomyocytes, and 
myofibrillar disarray were apparent. Wavy myofibrils, ab-
normal pattern of striations, disrupted intercalated discs and 
abnormal mitochondrial arrangements were identified (Fig. 
2A). Myofilaments derangement, partial necrosis, interca-
lated disc dissociation and disintegration of filaments were 
also  observed  (Fig.  2B).  Irregularities  of  the  sarcomere, 
lower concentration of ANF granules in the perinuclear area 
and disrupted nuclear chromatin were clearly observed (Fig. 
2C). In addition, swollen mitochondria with lysis of its cris-
tae and dissolution of the matrix were clearly observed. The 
intermembrane space of the mitochondria had expanded. In 
addition, specimens revealed decreased density of the sar-
coplasm and marked heterogeneity in the myofibril pattern 
with ruptures and loss of continuity of the myofilaments 
(Fig. 2D).
Group  III  (Amiodarone  and  alpha  tocopherol  treated 
rats)
Concomitant administration of vitamin E with amiodarone 
showed a considerable protection of the atrial tissues. Mi-
croscopic study of the atrial tissue of this group showed that 
the  sarcoplasm  was  occupied  by  normal  myofibrils  with 
clear striations and others had been disrupted. These changes 
did not demonstrate marked cardiac damage as in the amiod-
arone-treated group, although occasional focal loss of some 
myofibrils was observed (Fig. 3A, 3B). There were no altera-
tions in mitochondrial morphology compared to the second 
group (preserved cristae, normal size and shape) (Fig. 3B).
Discussion
  
Amiodarone produces its effect as an antiarrhythmic agent 
by employing different mechanisms of action. It is primarily 
a potassium channel blocker, but it can also block sodium 
and calcium channels in addition to beta- and alpha-adrener-
gic receptors [25]. The clinical use of amiodarone has been 
limited to refractory ventricular arrhythmias because of high 
incidence of side effects, which can be fatal [26]. Most cases 
of reported amiodarone cardiac toxicity are attributed to its 
electrophysiological effects, such as bradycardia, heart block 
and  proarrhythmia,  whereas  the  reported  histopathologi-
cal effects were limited mainly to non-cardiac tissues [27]. 
Hence, our current study is unique because it is the first in 
vivo study that demonstrates the ultrastructural changes due 
to amiodarone in its target cardiac cells.
Our study confirmed the toxic effects of amiodarone on 
mitochondrial morphology. The atrial specimens from the 
amiodarone-treated  group  showed  swollen  mitochondria 
with lysis of its cristae and dissolution of the matrices. The 
spaces between the outer and inner membranes of the mito-
chondria were clearly enlarged. Our findings support previ-
ous reported studies that showed that amiodarone induced 
perturbations and ultrastructural changes in mitochondrial 
structure of other non-cardiac tissues [28, 16]. The swelling 
of the mitochondria could result from failure of the osmotic 
control mechanism and/or decreased production of adenos-
ine triphosphate with subsequent influx of water resulting in 
breakdown of the inner membranes [29-31]. Furthermore, it 
is possible that oxidative stress due to an increased amount 
of oxygen free radicals could cause oxidative damage to the 
mitochondria and release cytochrome C from mitochondrial 
Figure 3. Electron micrographs from cardiac atria of amiodarone- and vitamin E-treated rats. A. A semithin section of cardiac muscle 
showing sarcoplasm of a cardiomyocyte occupied by normal myofibril striations (m), and other myofibrils (stars) appear disrupted. 
Dissociation of myofibrils in some (stars) and normal pattern (m) in others. B. ANF granules is still less in size (An) while the mito-
chondria (M) were preserved with its cristae (Bar = 1 µm). (x: 1000).
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intermembrane space, thus inducing apoptosis [32]. The re-
duced adenosine triphosphate production could also result 
in other changes, such as myofilaments derangement, par-
tial necrosis, intercalated disc dissociation and disintegration 
of filaments along with irregularities of the sarcomere [31]. 
The alterations of the sarcolemma in cells with end-stage de-
generation were associated with loss of myofibrils, loss of 
junctional contacts with adjacent cells and marked surface 
irregularity. Remodelling of the cell surfaces is an important 
feature of the cellular response to the stimuli of hypertrophy 
or degeneration [33]. Myofibril loss and sarcomere disarray 
are the most obvious structural changes in human cardiomy-
opathy and failing hearts [34].
The ANF-granules in the atria of rats treated with amio-
darone alone were less concentrated and smaller in size. The 
enhancement of ANF synthesis in the cells to overcome car-
diac overload, as in advanced heart failure, led to a reduction 
of the granule size with subsequent decrease in the levels 
of atrial ANF mRNA and plasma ANF in the course of the 
down regulation [35-37].
Concomitant administration of vitamin E with amioda-
rone, showed a considerable preservation of atrial architec-
ture. The protective effects of vitamin E against ultrastruc-
tural changes in other tissues, such as those of the lung and 
liver, have been reported [38, 19, 20]. The possible mecha-
nism of the protective effect of vitamin E on cardiomyocytes 
may be the result of several factors, including decreased cel-
lular amiodarone accumulation, decreased fat rancidisation, 
increased membrane stabilisation, altered profibrotic gene 
expression, free radical scavenging and decreased apoptosis 
[39-42].
Although the protective benefit of vitamin E co-admin-
istration  against  amiodarone-induced  cardiomyotoxicity 
is clearly observed in this report, the exact mechanism of 
this protection is not yet clear. The worrisome mechanism is 
that Vitamin E may negatively affect the antiarrhythmic ef-
ficacy of amiodarone. Furthermore, replicating the beneficial 
effects of vitamin E as antioxidant usually fails in clinical 
studies. The exact explanation for these conflicting results 
is not yet evident. However, Zoulin made a very interest-
ing observation when he compared the results from animal 
and in vitro studies with results from human clinical trials. 
He found that the animals used in the antioxidative stress 
trials  were  already  at  abnormal  levels  of  stress,  whereas 
high-powered clinical trials lacked the confounding effect of 
stress and revealed no benefit or adverse outcome. However, 
smaller  clinical  studies  involving  patients  with  abnormal 
levels of stress, for example, studies involving diabetic pa-
tients, show some benefits. He concluded that antioxidant in-
tervention during the so-called (WOPS) “Window Period for 
Oxidative Stress Attenuating Intervention” will show maxi-
mum benefit, whereas intervention outside this window will 
show no benefit or may even cause harm [43, 44]. Cardiac 
patients who require amiodarone therapy usually suffer from 
advanced heart disease, and their cardiac cells are expected 
to be under an abnormally high level of oxidative stress. 
Adding amiodarone to their drug regime, though effective 
in reducing arrhythmias, may lead to further progressive loss 
of myocardium and death due to pump failure rather than 
the arrhythmias themselves [45-47]. Therefore, it would be 
wise to consider adding antioxidant agents such as vitamin E 
when amiodarone use is contemplated.
Conclusion
It is evident that amiodarone administered over a short peri-
od results in significant cardiac ultrastructural changes while 
concomitant  administration  of  vitamin  E  provides  some 
protection against these adverse effects. This finding raises 
a concern about the long-term use of amiodarone on the ul-
trastructure of the heart.
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